Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St loses over 1% amid fading rate-cut hopes
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
October 4, 2016 1:38 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Summit Therapeutics plc (NASDAQ: SMMT) to $30.00 (from $22.00) after the company licensed out European rights to Phase II candidate ezutromid to Sarepta.
Messer commented, "We believe this deal... More
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM EDTBaird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).
Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM EDTRBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it removes a potential competitive threat with just $40M for access to competitor's drugs. He also said it makes the Sarepta more attractive as a takeover.
"Buying into this early-stage potential... More
Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
October 4, 2016 8:56 AM EDTSummit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive... More
Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
October 4, 2016 8:44 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $76 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company Sarepta and Summit (NASDAQ: SMMT) announced a licensing and collaboration agreement for EU rights to Summit's utrophin modulation programs... More
Threat of 'hard Brexit' pulls down Wall Street
October 4, 2016 7:44 AM EDTBy Noel Randewich
(Reuters) - U.S. stocks dropped on Tuesday as investors fretted about Britain's exit from the European Union and the prospect of a Federal Reserve interest rate hike in coming months.
It was the second straight session of losses on Wall Street, where investors were already on edge due to the uncertainty of a tight race ahead of the Nov. 8 presidential election.
Sterling slid to its lowest in more than three decades after British Prime Minister Theresa May said the country's divorce from the EU will not be "plain sailing" and... More
Summit Therapeutics (SMMT) will resume trading at 7:30am ET
October 4, 2016 7:08 AM EDTSummit Therapeutics (NASDAQ: SMMT) will resume trading at 7:30am EDT.
... More
